Cantor Fitzgerald analyst Elemer Piros maintained a Buy rating on Spark Therapeutics (ONCE) today and set a price target of $103. The company’s shares opened today at $43.40, close to its 52-week low of $35.63.
Piros commented:
“We rate Spark Therapeutics Overweight. ONCE focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. With lead candidate LUXTURNA, Spark has become the first company in the U.S. with an approval for an in-vivo gene therapy product. 12-month price target is determined by the sum of the risk-adjusted NPV for the after-tax and discounted value of the programs analyzed, a platform value for the remaining pipeline and YE19 cash.”
According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -9.9% and a 36.7% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Proteostasis Therapeutics Inc, and Strongbridge Biopharma Plc.
Spark Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $62.18, representing a 43.3% upside. In a report issued on November 26, Raymond James also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $96.59 and a one-year low of $35.63. Currently, Spark Therapeutics has an average volume of 574.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.
